Theralase Technologies (TSE:TLT) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Theralase Technologies has launched a new clinical study site at St. Joseph’s Healthcare Hamilton for its bladder cancer treatment using Ruvidar, achieving a complete response rate of over 61% in its Phase II trials. The company’s innovative anti-cancer therapy has shown promising results in treating BCG-Unresponsive Non-Muscle Invasive Bladder Cancer, with a total response rate of over 68%.
For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.
